Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma.

Tatsuaki SumiyoshiKenichiro UemuraRyuta ShintakuyaKenjiro OkadaKenta BabaTakumi HaradaMasahiro SerikawaYasutaka IshiiShinya NakamuraKoji ArihiroYoshiaki MurakamiShinya Takahashi

Published in: Annals of surgical oncology (2024)

Only patients with normal CA19-9 and DUPNA-2 values should be diagnosed with early-stage PDAC.

Keyphrases

early stage
protein kinase
sentinel lymph node
squamous cell carcinoma
lymph node
neoadjuvant chemotherapy